Detail of "133343-34-7"

Reference

Regulation of expression of transgenes delivered by adeno-associated virus vectors using inhibitors of proteasome function

Regulation of expression of transgenes delivered by adeno-associated virus vectors using inhibitors of proteasome function. Hirsch, Raphael; Jennings, Kristi J. (Children's Hospital Research Foundation, USA). PCT Int. Appl. WO 2002101012 A2 19 Dec 2002, 62 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C12N. APPLICATION: WO 2002-US18194 10 Jun 2002. PRIORITY: US 2001-PV297125 8 Jun 2001. DOCUMENT TYPE: Patent CA Section: 3 (Biochemical Genetics) Section cross-reference(s): 1 The present invention provides for methods regulating the expression of therapeutic genes delivered by adeno-assocd. virus (AAV) vectors both in vitro and in vivo. Specifically, the present invention provides for methods of using adeno-assocd. virus for transduction of a target gene in a variety of tissues wherein the expression of the transgene is regulated by administration of a proteasome inhibitor. 133343-34-7 which is the cas registry number is also used here.There are some reagents like 133343-34-7 is used in this study. Treatment of animal cells with proteasome inhibitors has been shown to increase the nuclear concn. of AAV particles and genomes. As an example, a therapeutic gene can be delivered in vivo by an adeno-assocd. virus to a tissue that is not normally transduced by adeno-assocd. virus. The host would then be administered a proteasome inhibitor in order to induce expression of the therapeutic gene. Hence, the proteasome inhibitor would be administered only when gene expression is desired. Human synoviocytes were transformed with an adeno-assocd. virus carrying a mouse interleukin 10 gene. Incubation of these cells with the proteasome inhibitor zLLL increased level of expression of the gene in a dose-dependent manner. The effect was transient although a long-term effect was predicted. The induction could be repeated by re-exposure to zLLL. In expts. with human synoviocytes and the mouse interleukin 4 gene, a 250-fold increase in the interleukin mRNA was seen upon induction with zLLL. ..

Regulation of expression of transgenes delivered by adeno-associated virus vectors using inhibitors of proteasome function

Regulation of expression of transgenes delivered by adeno-associated virus vectors using inhibitors of proteasome function. Hirsch, Raphael; Jennings, Kristi J. (Children's Hospital Research Foundation, USA). PCT Int. Appl. WO 2002101012 A2 19 Dec 2002, 62 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C12N. APPLICATION: WO 2002-US18194 10 Jun 2002. PRIORITY: US 2001-PV297125 8 Jun 2001. DOCUMENT TYPE: Patent CA Section: 3 (Biochemical Genetics) Section cross-reference(s): 1 The present invention provides for methods regulating the expression of therapeutic genes delivered by adeno-assocd. virus (AAV) vectors both in vitro and in vivo. Specifically, the present invention provides for methods of using adeno-assocd. virus for transduction of a target gene in a variety of tissues wherein the expression of the transgene is regulated by administration of a proteasome inhibitor. 133343-34-7 which is the cas registry number is also used here.There are some reagents like 133343-34-7 is used in this study. Treatment of animal cells with proteasome inhibitors has been shown to increase the nuclear concn. of AAV particles and genomes. As an example, a therapeutic gene can be delivered in vivo by an adeno-assocd. virus to a tissue that is not normally transduced by adeno-assocd. virus. The host would then be administered a proteasome inhibitor in order to induce expression of the therapeutic gene. Hence, the proteasome inhibitor would be administered only when gene expression is desired. Human synoviocytes were transformed with an adeno-assocd. virus carrying a mouse interleukin 10 gene. Incubation of these cells with the proteasome inhibitor zLLL increased level of expression of the gene in a dose-dependent manner. The effect was transient although a long-term effect was predicted. The induction could be repeated by re-exposure to zLLL. In expts. with human synoviocytes and the mouse interleukin 4 gene, a 250-fold increase in the interleukin mRNA was seen upon induction with zLLL. ..